BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 36503248)

  • 1. Structure-Based Design of a Dual-Targeted Covalent Inhibitor Against Papain-like and Main Proteases of SARS-CoV-2.
    Yu W; Zhao Y; Ye H; Wu N; Liao Y; Chen N; Li Z; Wan N; Hao H; Yan H; Xiao Y; Lai M
    J Med Chem; 2022 Dec; 65(24):16252-16267. PubMed ID: 36503248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diphenyl Diselenide and SARS-CoV-2:
    Omage FB; Madabeni A; Tucci AR; Nogara PA; Bortoli M; Rosa ADS; Neuza Dos Santos Ferreira V; Teixeira Rocha JB; Miranda MD; Orian L
    J Chem Inf Model; 2023 Apr; 63(7):2226-2239. PubMed ID: 36952618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ebselen derivatives inhibit SARS-CoV-2 replication by inhibition of its essential proteins: PL
    Zmudzinski M; Rut W; Olech K; Granda J; Giurg M; Burda-Grabowska M; Kaleta R; Zgarbova M; Kasprzyk R; Zhang L; Sun X; Lv Z; Nayak D; Kesik-Brodacka M; Olsen SK; Weber J; Hilgenfeld R; Jemielity J; Drag M
    Sci Rep; 2023 Jun; 13(1):9161. PubMed ID: 37280236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishing an Analogue Based In Silico Pipeline in the Pursuit of Novel Inhibitory Scaffolds against the SARS Coronavirus 2 Papain-Like Protease.
    Hajbabaie R; Harper MT; Rahman T
    Molecules; 2021 Feb; 26(4):. PubMed ID: 33672721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual Inhibitors of Main Protease (M
    Mondal S; Chen Y; Lockbaum GJ; Sen S; Chaudhuri S; Reyes AC; Lee JM; Kaur AN; Sultana N; Cameron MD; Shaffer SA; Schiffer CA; Fitzgerald KA; Thompson PR
    J Am Chem Soc; 2022 Nov; 144(46):21035-21045. PubMed ID: 36356199
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Tronco Pauletto PJ; Omage FB; Delgado CP; Nogara PA; Teixeira Rocha JB
    Curr Drug Discov Technol; 2023; 20(2):e101022209771. PubMed ID: 36221883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-throughput screening of SARS-CoV-2 main and papain-like protease inhibitors.
    Zang Y; Su M; Wang Q; Cheng X; Zhang W; Zhao Y; Chen T; Jiang Y; Shen Q; Du J; Tan Q; Wang P; Gao L; Jin Z; Zhang M; Li C; Zhu Y; Feng B; Tang B; Xie H; Wang MW; Zheng M; Pan X; Yang H; Xu Y; Wu B; Zhang L; Rao Z; Yang X; Jiang H; Xiao G; Zhao Q; Li J
    Protein Cell; 2023 Jan; 14(1):17-27. PubMed ID: 36726755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unravelling lead antiviral phytochemicals for the inhibition of SARS-CoV-2 M
    Gurung AB; Ali MA; Lee J; Farah MA; Al-Anazi KM
    Life Sci; 2020 Aug; 255():117831. PubMed ID: 32450166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimating the binding energetics of reversible covalent inhibitors of the SARS-CoV-2 main protease: an
    Awoonor-Williams E
    Phys Chem Chem Phys; 2022 Oct; 24(38):23391-23401. PubMed ID: 36128834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-based design of SARS-CoV-2 papain-like protease inhibitors.
    Jadhav P; Huang B; Osipiuk J; Zhang X; Tan H; Tesar C; Endres M; Jedrzejczak R; Tan B; Deng X; Joachimiak A; Cai J; Wang J
    Eur J Med Chem; 2024 Jan; 264():116011. PubMed ID: 38065031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Azapeptides with unique covalent warheads as SARS-CoV-2 main protease inhibitors.
    Khatua K; Alugubelli YR; Yang KS; Vulupala VR; Blankenship LR; Coleman D; Atla S; Chaki SP; Geng ZZ; Ma XR; Xiao J; Chen PH; Cho CD; Sharma S; Vatansever EC; Ma Y; Yu G; Neuman BW; Xu S; Liu WR
    Antiviral Res; 2024 May; 225():105874. PubMed ID: 38555023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting SARS-CoV-2 Main Protease for Treatment of COVID-19: Covalent Inhibitors Structure-Activity Relationship Insights and Evolution Perspectives.
    La Monica G; Bono A; Lauria A; Martorana A
    J Med Chem; 2022 Oct; 65(19):12500-12534. PubMed ID: 36169610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mass Spectrometric Assays Reveal Discrepancies in Inhibition Profiles for the SARS-CoV-2 Papain-Like Protease.
    Brewitz L; Kamps JJAG; Lukacik P; Strain-Damerell C; Zhao Y; Tumber A; Malla TR; Orville AM; Walsh MA; Schofield CJ
    ChemMedChem; 2022 May; 17(9):e202200016. PubMed ID: 35085423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computer-aided drug design for the pain-like protease (PL
    Gao H; Dai R; Su R
    Biomed Pharmacother; 2023 Mar; 159():114247. PubMed ID: 36689835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Easy access to α-ketoamides as SARS-CoV-2 and MERS M
    Pelliccia S; Cerchia C; Esposito F; Cannalire R; Corona A; Costanzi E; Kuzikov M; Gribbon P; Zaliani A; Brindisi M; Storici P; Tramontano E; Summa V
    Eur J Med Chem; 2022 Dec; 244():114853. PubMed ID: 36332546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-Based Identification of Naphthoquinones and Derivatives as Novel Inhibitors of Main Protease M
    Santos LH; Kronenberger T; Almeida RG; Silva EB; Rocha REO; Oliveira JC; Barreto LV; Skinner D; Fajtová P; Giardini MA; Woodworth B; Bardine C; Lourenço AL; Craik CS; Poso A; Podust LM; McKerrow JH; Siqueira-Neto JL; O'Donoghue AJ; da Silva Júnior EN; Ferreira RS
    J Chem Inf Model; 2022 Dec; 62(24):6553-6573. PubMed ID: 35960688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-Based Design of Potent Peptidomimetic Inhibitors Covalently Targeting SARS-CoV-2 Papain-like Protease.
    Wang Q; Chen G; He J; Li J; Xiong M; Su H; Li M; Hu H; Xu Y
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization Rules for SARS-CoV-2 M
    Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
    Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Silico Drug Repositioning to Target the SARS-CoV-2 Main Protease as Covalent Inhibitors Employing a Combined Structure-Based Virtual Screening Strategy of Pharmacophore Models and Covalent Docking.
    Vázquez-Mendoza LH; Mendoza-Figueroa HL; García-Vázquez JB; Correa-Basurto J; García-Machorro J
    Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.